July 2018 FDA Recall Moxifloxacin by Lupin Pharmaceuticals Inc.
D-1050-2018 - Failed Impurities/Degradation Specifications

This Class III drug recall was voluntarily initiated by Lupin Pharmaceuticals Inc. on July 26, 2018 for the product Moxifloxacin. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed in Product was distributed throughout the United States and the recall is currently terminated.

Recall Number: D-1050-2018

Reason for Recall
Failed Impurities/Degradation Specifications: An out-of-specification result in the related substance test during three month long-term stability study.
Initiated
07-26-2018
Reported
08-08-2018
Quantity
13,896 bottles

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Lupin Pharmaceuticals Inc.
Product was distributed throughout the United States
Moxifloxacin Ophthalmic Solution USP, 0.5%, 5 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, Maryland 21202 United States, Manufactured by: Lupin Limited Pithampur (M.P.) 454 775, INDIA, NDC 68180-422-01

Batch or Lot Expiration Information

Lot# : H800393, Exp. 01/2020

Affected Packages Involved in this Recall